Zacks.com on MSN3d
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend
Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...
pharmaphorum5d
Roche names Teresa Graham as its new pharma chief
Like Anderson, Graham is a veteran of Roche's Genentech unit in the US ... including the launches of Vabysmo (faricimab) for age-related macular degeneration (AMD) and lymphoma therapy Lunsumio ...
pharmaphorum6d
After earlier rejection, high-dose Eylea clears FDA
Along with greater patient and physician convenience, the new version could help Regeneron and Bayer fend off a deepening challenge from Roche with its bispecific VEGF and Ang-2 inhibitor Vabysmo ...
Reuters5d
Roche Holding AG
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...